#JPM20: 'The NPV is al­ways wrong.' Take­da preps an­oth­er spin­out — this time on psych

Ed­i­tor’s Note: End­points News is re­port­ing live from #JPM20 af­ter kick­ing things off with an ac­tion-packed event, which you can re­play here. What fol­lows is a stream of tid­bits we have col­lect­ed while wan­der­ing around Union Square in San Fran­cis­co. Check back in through­out the week for up­dates by John Car­roll and Ja­son Mast.

SAN FRAN­CIS­CO — A year ago Take­da CEO Christophe We­ber and R&D chief Andy Plump ar­rived at JP Mor­gan right on the heels of clos­ing their big Shire buy­out. Now they’re back af­ter shak­ing up the port­fo­lio, boost­ing R&D spend­ing by about 50% to $4.5 bil­lion and ad­just­ing the pipeline — a task which isn’t quite fin­ished yet.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN